{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T08:22:39Z","timestamp":1765959759496,"version":"3.40.5"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","internationaljournalofcardiology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.ijcard.2014.10.164","type":"journal-article","created":{"date-parts":[[2014,10,30]],"date-time":"2014-10-30T01:09:12Z","timestamp":1414631352000},"page":"146-152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Absolute change in fasting plasma glucose over 12months is associated with 2-year and 5-year major adverse cardiovascular events in patients with drug-eluting stent implants"],"prefix":"10.1016","volume":"179","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5187-8310","authenticated-orcid":false,"given":"Dong Oh","family":"Kang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong Seog","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6090-869X","authenticated-orcid":false,"given":"Byung Geol","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunmi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Park","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun Ki","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2544-2422","authenticated-orcid":false,"given":"Sung Il","family":"Im","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Oh","family":"Na","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheol Ung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong Euy","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eung Ju","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-Woon","family":"Rha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang Gyu","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong Joo","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2014.10.164_bb0005","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)","volume":"285","author":"Expert Panel on Detection E, Treatment of High Blood Cholesterol in A","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2014.10.164_bb0010","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jacc.2004.07.001","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines","volume":"44","author":"Grundy","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2014.10.164_bb0015","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJM199807233390404","article-title":"Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction","volume":"339","author":"Haffner","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2014.10.164_bb0020","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2337\/diacare.16.2.434","article-title":"Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial","volume":"16","author":"Stamler","year":"1993","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ijcard.2014.10.164_bb0025","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMoa021993","article-title":"Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events","volume":"347","author":"Ridker","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2014.10.164_bb0030","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nature01323","article-title":"Inflammation in atherosclerosis","volume":"420","author":"Libby","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.ijcard.2014.10.164_bb0035","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.jacc.2009.09.009","article-title":"Inflammation in atherosclerosis: from pathophysiology to practice","volume":"54","author":"Libby","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2014.10.164_bb0040","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Emerging Risk Factors C","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2014.10.164_bb0045","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1001\/archinternmed.2011.2","article-title":"Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors","volume":"171","author":"Wannamethee","year":"2011","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ijcard.2014.10.164_bb0050","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/clc.4960240416","article-title":"Random fasting hyperglycemia as cardiovascular risk factor in the elderly: a 6-year longitudinal study","volume":"24","author":"Antonicelli","year":"2001","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.ijcard.2014.10.164_bb0055","doi-asserted-by":"crossref","first-page":"960","DOI":"10.2337\/diab.43.8.960","article-title":"NIDDM and its metabolic control predict coronary heart disease in elderly subjects","volume":"43","author":"Kuusisto","year":"1994","journal-title":"Diabetes"},{"key":"10.1016\/j.ijcard.2014.10.164_bb0060","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.2337\/diacare.21.7.1167","article-title":"Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study","volume":"21","author":"Wei","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ijcard.2014.10.164_bb0065","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/S0140-6736(07)60716-8","article-title":"The safety of statins in clinical practice","volume":"370","author":"Armitage","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2014.10.164_bb0070","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2014.10.164_bb0075","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","author":"Cholesterol Treatment Trialists C","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2014.10.164_bb0080","doi-asserted-by":"crossref","first-page":"III39","DOI":"10.1161\/01.CIR.0000131517.20177.5a","article-title":"Beneficial cardiovascular pleiotropic effects of statins","volume":"109","author":"Davignon","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2014.10.164_bb0085","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/CRD.0b013e3181f52a7f","article-title":"The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in cardiovascular disease: a comprehensive review","volume":"18","author":"Mihos","year":"2010","journal-title":"Cardiol. Rev."},{"key":"10.1016\/j.ijcard.2014.10.164_bb0090","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.2337\/dc09-0738","article-title":"Statin therapy and risk of developing type 2 diabetes: a meta-analysis","volume":"32","author":"Rajpathak","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ijcard.2014.10.164_bb0095","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2014.10.164_bb0100","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2014.10.164_bb0105","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2014.10.164_bb0110","doi-asserted-by":"crossref","first-page":"724","DOI":"10.2337\/diabetes.51.3.724","article-title":"Hypoglycemia-associated autonomic failure in advanced type 2 diabetes","volume":"51","author":"Segel","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.ijcard.2014.10.164_bb0115","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2014.10.164_bb0120","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2014.10.164_bb0125","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1056\/NEJMoa1003795","article-title":"Severe hypoglycemia and risks of vascular events and death","volume":"363","author":"Zoungas","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2014.10.164_bb0130","first-page":"2","article-title":"Do statins interfere with lifestyle intervention in the prevention of diabetes in primary healthcare? One-year follow-up of the FIN-D2D project","author":"Rautio","year":"2012","journal-title":"BMJ Open"},{"key":"10.1016\/j.ijcard.2014.10.164_bb0135","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2310\/JIM.0b013e318197ec8b","article-title":"Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients","volume":"57","author":"Sukhija","year":"2009","journal-title":"J. Invest. Med."},{"key":"10.1016\/j.ijcard.2014.10.164_bb0140","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jacc.2009.10.053","article-title":"Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients","volume":"55","author":"Koh","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2014.10.164_bb0145","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/j.1464-5491.2011.03553.x","article-title":"Effects of rosuvastatin and atorvastatin on glycaemic control in type 2 diabetes\u2014the CORALL Study","volume":"29","author":"Simsek","year":"2012","journal-title":"Diabet. Med."},{"key":"10.1016\/j.ijcard.2014.10.164_bb0150","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1210\/edrv-3-3-299","article-title":"The role of lipoproteins in steroidogenesis and cholesterol metabolism in steroidogenic glands","volume":"3","author":"Gwynne","year":"1982","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.ijcard.2014.10.164_bb0155","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1007\/BF03345757","article-title":"A multi-center, open label, crossover designed prospective study evaluating the effects of lipid lowering treatment on steroid synthesis in patients with Type 2 diabetes (MODEST Study)","volume":"32","author":"Kanat","year":"2009","journal-title":"J. Endocrinol. Invest."},{"key":"10.1016\/j.ijcard.2014.10.164_bb0160","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00392-004-1003-2","article-title":"Does statin therapy influence steroid hormone synthesis?","volume":"93","author":"Bohm","year":"2004","journal-title":"Z. Kardiol."},{"key":"10.1016\/j.ijcard.2014.10.164_bb0165","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/0026-0495(93)90272-P","article-title":"Long-term endocrine function in hypercholesterolemic patients treated with pravastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor","volume":"42","author":"Dobs","year":"1993","journal-title":"Metab. Clin. Exp."},{"key":"10.1016\/j.ijcard.2014.10.164_bb0170","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1053\/meta.2000.7716a","article-title":"Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia","volume":"49","author":"Dobs","year":"2000","journal-title":"Metab. Clin. Exp."},{"key":"10.1016\/j.ijcard.2014.10.164_bb0175","first-page":"836","article-title":"Sustained therapy with 3-hydroxy-3-methylglutaryl-coenzyme-A reductase inhibitors does not impair steroidogenesis by adrenals and gonads","volume":"80","author":"Travia","year":"1995","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ijcard.2014.10.164_bb0180","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1001\/archinte.167.14.1545","article-title":"Short-term variability in measures of glycemia and implications for the classification of diabetes","volume":"167","author":"Selvin","year":"2007","journal-title":"Arch. Intern. Med."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527314021081?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527314021081?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T00:23:17Z","timestamp":1538094197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527314021081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":36,"alternative-id":["S0167527314021081"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2014.10.164","relation":{},"ISSN":["0167-5273"],"issn-type":[{"type":"print","value":"0167-5273"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Absolute change in fasting plasma glucose over 12months is associated with 2-year and 5-year major adverse cardiovascular events in patients with drug-eluting stent implants","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2014.10.164","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}